|Day Low/High||1.41 / 1.53|
|52 Wk Low/High||0.60 / 2.78|
Walk to End Alzheimer's is Largest Fundraiser Dedicated to Alzheimer's Care, Support and Research Programs
Contract funded by the Patient-Centered Outcomes Research Institute to Study Treatment Approaches for Nursing Home Residents with Dementia
Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (NASDAQ: SGEN) announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.
The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 657,491 share increase in total short interest for Genesis Healthcare Inc , to 2,874,971, an increase of 29.65% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Awards program recognizes region's most innovative companies and doctors
3rd PowerBack Rehabilitation Location in New Jersey
Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Seattle Genetics, Inc.
Centers recognized by national program for commitment to quality care
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.